Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market 2025: Rising Prevalence of Parkinson’s Disease Driving Growth

The Business Research Company's Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 28, 2025 /EINPresswire.com/ -- Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

Shedding light on the Vesicular Monoamine Transporter 2 VMAT2 inhibitor market, it has seen a rapid expansion in recent years and will continue to flourish going forward. The market size was estimated at $1.13 billion in 2024 and is predicted to grow to $1.25 billion in 2025, recording an impressive compound annual growth rate CAGR of 10.6%. Several factors have contributed to this growth during the historic period, including increasing prevalence of movement disorders, mounting demand for effective treatment options, growing awareness about tardive dyskinesia, a surge in the aging population, and a rising preference for oral formulations.

Is the VMAT2 Inhibitor Market Growth Poised to Continue Its Rapid Surge in Coming Years?
Yes, the Vesicular Monoamine Transporter 2 VMAT2 inhibitor market is anticipated to witness a significant expansion in the next few years. The market size is forecasted to reach $1.85 billion in 2029, reflecting a compound annual growth rate CAGR of 10.3%. This projected expansion during the forecast period is expected due to the surge in neurodegenerative diseases, the adoption of targeted therapies, a shift towards personalized medicine, increased investment in R&D, and rising awareness about psychiatric and movement disorders. Major market trends are advancements in neurological research, progressive drug formulations, a shift towards individualized and precision medicine, the development of next-generation VMAT2 inhibitors, and the integration of digital health technologies.

Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=21317&type=smp

What's Affecting Vesicular Monoamine Transporter 2 VMAT2 Inhibitors Market Expansion?
Presently, the rise in Parkinson’s disease cases is largely driving the growth of the VMAT2 inhibitor market. Parkinson's disease, a progressive neurological disorder that results in impaired movement due to the loss of dopamine-producing cells in the brain, is prevalent more than ever. The rise in Parkinson's disease is primarily attributed to an aging population, improved diagnosis, environmental factors such as toxins, genetic influences, and widespread awareness of the condition. VMAT2 inhibitors aid in the management of Parkinson's symptoms by modulating dopamine release and reducing tremors and dyskinesia. In December 2022, according to the Parkinson's Foundation, a US-based nonprofit organization, nearly 90,000 people were diagnosed with Parkinson's disease in the U.S., marking a 50% increase from the previous estimate of 60,000 annual diagnoses. Therefore, it is the increased prevalence of Parkinson’s disease that is heavily driving the growth of the Vesicular Monoamine Transporter 2 VMAT2 inhibitor market.

Which Lead Players Dominate the VMAT2 Inhibitor Market?
The vesicular monoamine transporter 2 VMAT2 inhibitor market is dominated by several players such as Thermo Fisher Scientific Inc., Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Otsuka Pharmaceutical, Astellas Pharma, Bausch Health Companies Inc., Avantor Inc., Sun Pharmaceutical Industries Limited, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Ventegra Inc., Mitsubishi Tanabe Pharma Corporation, Biomol GmbH.

What's the Latest Trend in Vesicular Monoamine Transporter 2 VMAT2 Inhibitors Market?
In a recent development, the key players in the vesicular monoamine transporter 2 VMAT2 inhibitors market are focusing on developing advanced formulations such as capsules to improve patient compliance, stabilize drugs, and optimize therapeutic effectiveness. Capsules, being a solid dosage form enclosed in a gelatin or HPMC shell, assist VMAT2 inhibitors by stabilizing the drug, ensuring precise dosing, and enhancing patient compliance. Neurocrine Biosciences Inc., a US-based biopharmaceutical company, launched Ingrezza Sprinkle valbenazine capsules in July 2024. This new formulation of the VMAT2 inhibitor Ingrezza was developed to ease administration for adults suffering from tardive dyskinesia and chorea associated with Huntington's disease who experience difficulty swallowing. Ingrezza Sprinkle offers the same effective dosing options as Ingrezza and can be administered either by sprinkling the contents of the capsule onto soft food or swallowing the capsule whole.

Order Your Report Now For A Swift Delivery: https://www.thebusinessresearchcompany.com/report/vesicular-monoamine-transporter-2-vmat2-inhibitor-global-market-report

How is the Vesicular Monoamine Transporter 2 VMAT2 Inhibitor Market Segmented?
The Vesicular Monoamine Transporter 2 VMAT2 Inhibitor Market can be delineated into several categories:

1 By Drugs: Tetrabenazine, Deutetrabenazine, Valbenazine, Other Drugs
2 By Route Of Administration: Oral, Other Administrations
3 By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4 By Application: Huntington’s Disease, Tardive Dyskinesia, Other Applications
5 By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

The sub-segments are as follows:
1 By Tetrabenazine: Huntington’s Disease Treatment, Tardive Dyskinesia Management, Tourette Syndrome Treatment
2 By Deutetrabenazine: Huntington’s Disease Chorea, Tardive Dyskinesia Treatment, Off-Label Movement Disorders
3 By Valbenazine: Tardive Dyskinesia Treatment, Tourette Syndrome Research, Other Hyperkinetic Movement Disorders
4 By Other Drugs: Investigational VMAT2 Inhibitors, Emerging Therapies For Movement Disorders, Off-Label Use In Neurological Conditions

What Are the Regional Insights of the VMAT2 Inhibitor Market?
Geographically, North America was the largest region in the vesicular monoamine transporter 2 VMAT2 inhibitor market in 2024. The regions covered in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Discover successful strategies and key players shaping the Vesicular Monoamine Transporter 2 VMAT2 Inhibitor Global Market by reading the full report.

Browse Through More Similar Reports By The Business Research Company:

Alpha Glucosidase Inhibitors Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report

Tyrosine Kinase Inhibitors Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report

Interleukin Inhibitors Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
X
LinkedIn